Essa Pharma Inc (EPIX) NPV

Sell:$1.62Buy:$1.74$0.01 (0.59%)

Prices delayed by at least 15 minutes
Sell:$1.62
Buy:$1.74
Change:$0.01 (0.59%)
Deal now
Prices delayed by at least 15 minutes
Sell:$1.62
Buy:$1.74
Change:$0.01 (0.59%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

Key people

David Ross Parkinson
President, Chief Executive Officer, Director
David Sidney Wood
Chief Financial Officer
Peter Virsik
Chief Operating Officer, Executive Vice President
Alessandra Cesano
Executive Vice President, Chief Medical Officer
Richard M. Glickman
Non-Executive Independent Chairman of the Board
Franklin M. Berger
Independent Director
Philip Kantoff
Independent Director
Alex Martin
Independent Director
Lauren Merendino
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA29668H7085
  • Market cap
    $75.02m
  • Employees
    35
  • Shares in issue
    44.39m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.